Companies › Medicenna Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Oct 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MDNA11 Beta-only IL-2 receptor agonist fused to albumin | IL2 | Phase 1 | Advanced Solid Tumor | Oct 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05086692 | MDNA11 | Phase 1 | Advanced Solid Tumor | Oncology | Oct 2028 |
Cash and short-term investments of 66m CAD on 2023-03-31; operating cash outflow about 52m CAD a year; runway about 15 months at that burn, to Jul 2024
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.